EDIT 10-KMar 9 '26
“In addition, in December 2023, we and Vertex Pharmaceuticals Incorporated ("Vertex") entered into a license agreement (the "Vertex License Agreement"), under which Vertex obtained a non-exclusive license for our Cas9 gene editing technology for ex vivo gene editing medicines targeting the BCL11A gene in the fields of SCD and TDT, including Vertex's CASGEVY TM (exagamglogene autotemcel).”
ZLAB · VRTX 10-KFeb 13 '26
“Zai licensed povetacicept for mainland China, Hong Kong SAR, Macau SAR, Taiwan region, and Singapore, while Ono licensed povetacicept for Japan and South Korea.”
EDIT 10-KMar 9 '26
“In connection with our collaboration with BMS, we have received an aggregate of $159.0 million in payments, which have primarily consisted of the initial upfront and amendment payments, development milestone payments, research funding support, and certain opt-in fees.”
ZLAB 10-KFeb 26 '26
“license agreement with Turning Point (a company later acquired by BMS) pursuant to which we obtained an exclusive license to develop and commercialize products containing repotrectinib (AUGTYRO) as an active ingredient in all human therapeutic indications in Greater China.”